QUEST DIAGNOSTICS INC (DGX) Form 8-K — Oct 22, 2026
Quest Diagnostics (NYSE: DGX) reported Q3 2026 revenues of $3.10 billion, up 10.0% year over year, with reported diluted EPS of $2.78 (up 28.7%) and adjusted diluted EPS of $3.00 (up 15.4%). The company raised its full year 2026 guidance, now expecting net revenues of $12.065-$12.105 billion and adjusted diluted EPS of $11.25-$11.35, up from prior ranges of $11.95-$12.05 billion and $11.05-$11.25 respectively. Growth was driven by 14.4% organic requisition volume growth across physician, hospital and consumer channels, plus productivity gains from automation and AI.
Key figures
- Eps
- 2.78
- Revenue
- 3097000000
- Guidance
- FY2026 net revenues raised to $12.065B-$12.105B (from $11.95B-$12.05B); reported diluted EPS raised to $10.21-$10.31; adjusted diluted EPS raised to $11.25-$11.35 (from $11.05-$11.25); cash from operations ~$1.90B; capex ~$550M.
- Net Income
- 312000000
- Revenue Yoy
- 10.0%
- Total Assets
- 17221000000
- Cash Position
- 797000000
- Capex q3
- 166000000
- Nine month revenue
- 9035000000
- Adjusted net income q3
- 338000000
- Adjusted diluted eps q3
- 3
- Adjusted eps growth yoy
- 15.4%
- Cash from operations q3
- 611000000
- Operating income q3 adjusted
- 517000000
- Operating income q3 reported
- 479000000
- Revenue per requisition change
- -4.2%
- Organic requisition volume growth
- 14.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.